Answer
Phesgo is indicated with chemotherapy for neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence, and for adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence.
Sources for this answer
- Phesgo 600 mg/600 mg, 1200 mg/600 mg solution for injectionRoche Products Limited · emc · SmPC §4.1 Therapeutic Indications · Version 7Document updated
Sources checked